Botulinum Toxin in the Treatment of Strabismus. a Review of Its Use and Effects
Total Page:16
File Type:pdf, Size:1020Kb
Disability and Rehabilitation, December 2007; 29(23): 1823 – 1831 Botulinum Toxin in the treatment of strabismus. A review of its use and effects LIONEL KOWAL1,2, ELAINE WONG1,2 & CLAUDIA YAHALOM3 1Ocular Motility Unit, Royal Victorian Eye and Ear Hospital, Melbourne, 2Centre for Eye Research, Australia, and 3Ophthalmology, Hadassah Hospital, Jerusalem, Israel Abstract Botulinum Toxin as a medical therapy was introduced by Dr Alan Scott more than 20 years ago. The first clinical applications of Botulinum Toxin type A (BT-A) were for the treatment of strabismus and for periocular spasms. Botulinum Toxin type A is often effective in small to moderate angle convergent strabismus (esotropia) of any cause, and may be an alternative to surgery in these cases. Botulinum Toxin type A may have a role in acute or chronic fourth and sixth nerve palsy, childhood strabismus and thyroid eye disease. The use of BT-A for strabismus varies enormously in different cities and countries for no apparent reason. Botulinum Toxin type A may be particularly useful in situations where strabismus surgery is undesirable. This may be in elderly patients unfit for general anaesthesia, when the clinical condition is evolving or unstable, or if surgery has not been successful. Botulinum Toxin type A can give temporary symptomatic relief in many instances of bothersome diplopia irrespective of the cause. Ptosis and acquired vertical deviations are the commonest complications encountered. Vision-threatening complications are rare. Repeated use of BT-A is safe. Keywords: Strabismus, Botulinum Toxin type A, ocular Motility disorders There are a small number of centres where BT-A is Introduction used frequently in the treatment of strabismus. The The use of Botulinum Toxin type A (BT-A) for Toxin Clinic at the Moorfields Eye Hospital in strabismus was first described and developed by the London had given 18,000 BT-A injections for stra- American ophthalmologist Dr Alan Scott in the early bismus by the end of 2005. The Gomez family of 1980s [1,2]. He personally trained hundreds of ophthalmologists in Madrid have given 7,000 BT-A ophthalmologist collaborators in its use (including injections for strabismus until 2005. These two groups, the author LK) and carefully collated data from his and that of the developer Alan Scott in San Francisco, own and their work over some years to demonstrate stand out as the most experienced centres inter- the effects of BT-A. Botulinum Toxin type A was nationally in the use of BT-A in strabismus. subsequently approved by the Food and Drug In Australia, there are about 10 ophthalmologists Authority [USA] for both adult strabismus and who have been trained in the use of BT-A for blepharospasm in 1989. Since then, BT-A has been strabismus, usually in London or San Francisco. used by a small number of ophthalmologists (usually Statistics on the use of BT-A in strabismus in strabismus specialists) as an easier and less invasive Australia are available from the Medicare Australia alternative to strabismus surgery in selected cases. website. The data does not include patients who are Regrettably, prospective randomized controlled trials treated in public hospitals or whose treatment is not on the use of BT-A in different strabismus entities billed through Medicare Australia, e.g., those paid by comparing the effect of BT-A to that of surgery have Workcover companies. Only 70 – 80 BT-A treat- yet to be performed. ments for strabismus a year are recorded on the Correspondence: Dr Lionel Kowal, The Private Eye Clinic, Level 3, 182 Victoria Parade, East Melbourne VIC 3002, Australia. E-mail: [email protected] ISSN 0963-8288 print/ISSN 1464-5165 online ª 2007 Informa UK Ltd. DOI: 10.1080/09638280701568189 1824 L. Kowal et al. Medicare Australia website (www.medicareaustra- rein sets are not ‘pure’ and there is some overlap. lia.gov.au) throughout the country. The primarily torsional muscles have a secondary Botulinum Toxin type A is usually injected directly vertical effect, and the primarily vertical muscles sets into the selected extraocular muscle in the ophthal- have a secondary torsional effect. In upgaze and mologists’ office under topical anaesthesia, usually downgaze the horizontal muscles may have a vertical with electromyographic (EMG) guidance. Patient effect, and the vertical muscles have a horizontal cooperation is required. The ‘chair time’ is typically effect. Fortunately most cases of strabismus are not 10 – 15 min, and time lost from work is typically of the highest degrees of complexity! 2 – 3 h. The effect of BT-A will start to be seen within Treating an imbalance surgically usually involves 2 – 4 days of the injection, it then causes an over- changing the length and tension of one or both correction for some weeks (‘the effect’), which then muscles of an agonist/antagonist set. Typically the wears off after 6 – 8 weeks leaving a permanent re- muscle that is pulling the eye out of alignment is alignment (‘the after-effect’) in many cases. repositioned (recessed) by effectively lengthening it Botulinum Toxin type A may be particularly (this changes the eye position) and changing the useful in situations where strabismus surgery is amount of torque it can generate (the change in undesirable. This may be in elderly patients unfit torque affects the medium – long-term stability of the for general anaesthesia, when the clinical condition is new eye position). The ‘pair’ of the weakened muscle evolving or unstable, or if surgery has not been is usually shortened (resected) to pull the eye away successful. Botulinum Toxin type A can give from its misaligned position to a more correct one. temporary symptomatic relief in many instances of bothersome diplopia irrespective of the cause. How BT-A works in strabismus Botulinum Toxin type A works by paralyzing the Strabismus extraocular muscle that is pulling the eye out of Strabismus arises when there is imbalance in alignment. In the initial period of paralysis, there will extraocular muscle function resulting in misalign- be an overcorrection of strabismus as the normally ment of the eye or eyes. The foveas will not both be functioning antagonist overpowers the paralysed directed at the same object and (if both eyes see well) muscle (‘the effect’). With this overcorrection there there will be diplopia and confusion. will be contraction of the antagonist and stretching of The muscular control of eye movements can be the paralysed muscle. During this time the lengths of likened to the reins of a horse – when one muscle the paralyzed muscle and its antagonist will change, contracts (agonist), the other relaxes (antagonist). and the length-tension curves within these muscles Both reins do not contract at the same time unless will also change. Histology shows a change in innervation is anomalous. There are 3 different sets sarcomere density. When the effect of BT-A wears of reins for each eye, for horizontal, vertical and off, some of these changes will persist, and a resultant torsional movements. The actions of the 3 sets of net change to the alignment of the eyes occurs (‘the muscle in one eye are intricately linked to the actions after-effect’). of the 3 sets of the other eye. Each rein forms part of For example, in the correction of small angle left one of 3 pairs of agonist and antagonist extraocular convergent strabismus, BT-A is injected into the left muscles, the primary actions of which are: medial rectus (LMR). This will paralyze the LMR for some weeks. During that time, the unopposed left (1) Horizontal movement: lateral rectus (LLR), will abduct the eye, and the eye (a) Medial rectus (MR) – adduction (mov- will be divergent (‘the effect’). Whilst the eye is ing the eye towards the nose) divergent the following changes are likely to occur: (b) Lateral rectus (LR) – abduction (towards the ear) (1) The LMR will be stretched and will lengthen; (2) Vertical movement: (2) The length-tension curve of the LMR will (a) Superior rectus (SR) – elevation change; (b) Inferior rectus (IR) – depression (3) The length-tension curve of the LLR will also (3) Torsional movement: change; (a) Superior oblique (SO) – intorsion (4) The LLR will shorten; and (clockwise rotation of the right eye, (5) Sarcomere density in both these muscles will anti- clockwise of the left eye) gradually change. (b) Inferior oblique (IO) – extorsion. When the LMR paralysis from the BT-A wears off, When there is an imbalance of one or more of these some of the changes in the lengths and length- muscles sets, strabismus results. The actions of the tension ratios in both the recently paralyzed and Botulinum toxin in the treatment of strabismus 1825 stretched LMR and the recently contracted LLR will (3) Injection under direct vision through a be retained and result in lessened misalignment, ‘the conjunctival incision prepared just for the after-effect’. BT-A injection; It is important to note that, in this LMR example, (4) Injection via subconjunctival lacrimal BT-A will not have an after-effect if the LLR is not cannula alongside a muscle [3]; or active – a functioning LLR is needed to pull the (5) Transconjunctival injection after grasping the LMR out and stretch it causing some temporary muscle with forceps and bunching it up [4]. overcorrection of the misalignment in order to have an after-effect. In one series, injection without EMG guidance in 40 The amount of after-effect (change in alignment) children with different types of convergent strabis- will be dependent on the final changes in the lengths mus has been shown to be reasonably successful with of the muscles after the stretching and contraction. a complication rate comparable to that incurred with The duration of the after-effect (stability of the new EMG guidance [5].